We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly)... Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs. Show more
- 2025 will be a transformational year for Incyte with multiple significant milestones, including four potential launches, four pivotal trial readouts, seven proof of concept data readouts and at...
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 9,502 shares of the Companyโs common stock to 14 new employees. The awards...
Incyte Corporation (Nasdaq: INCY) announced today that it granted equity inducement awards to Mohamed Issa, the Companyโs new Executive Vice President, Head of U.S. Oncology, pursuant to the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.41 | -1.92255249523 | 73.34 | 74.01 | 69.53 | 1692462 | 71.89476675 | CS |
4 | 2.765 | 3.99768669125 | 69.165 | 75.04 | 66.33 | 1716255 | 69.97704657 | CS |
12 | 6.44 | 9.83356237594 | 65.49 | 83.95 | 64.76 | 2114565 | 73.0926372 | CS |
26 | 8.44 | 13.2934320365 | 63.49 | 83.95 | 60.18 | 1964954 | 68.79113624 | CS |
52 | 9.34 | 14.9225115833 | 62.59 | 83.95 | 50.3498 | 2302532 | 62.90483452 | CS |
156 | -3.78 | -4.99273543785 | 75.71 | 86.29 | 50.27 | 1861524 | 66.9324616 | CS |
260 | -9.19 | -11.3288954635 | 81.12 | 111.05 | 50.27 | 1704535 | 72.16210327 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions